PRLog - March 15, 2012 - NEEDHAM, Mass. -- NEEDHAM, MASS. – Cambridge Healthtech Institute’s Insight Pharma Reports announces the Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity Report
GBI Research has released its latest research, “Licensing Strategies of Large Pharmaceutical Companies - Weak R&D Pipelines and the Patent Cliff Stimulate In-Licensing Activity” which provides insights into the licensing agreements of large pharmaceutical companies. The report provides an in-depth analysis of the major licensing agreement trends in the pharmaceutical industry along with product and technology licensing trends. In addition, the report also analyzes the top 20 pharmaceutical companies with respect to the licensing agreement activities. The report is built using data and information sourced from proprietary databases, primary and secondary research, and in-house analysis by GBI Research’s team of industry experts.
Scope of this report includes:
• Major market trends that are expected to shape the licensing and deal making landscape in pharmaceutical industry
• Trends in deals for product licensing and technology licensing agreements.
• Extensive research and analysis of the licensing activity of large pharmaceutical companies.
• Licensing and deal making segmentation of top 20 in the pharmaceutical companies by phase, type, geography and value
• Company profiles of leading biotech companies active in licensing and deal making
For more information and to purchase this Insight Pharma Report, visit: http://www.InsightPharmaReports.com
About Insight Pharma Reports
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets. Insight Pharma Reports are used by leading pharmaceutical, biotech, diagnostic, consulting, and financial companies to keep abreast of the latest advances in pharmaceutical R&D, their potential applications and business impacts, and their current and future position in the marketplace. Insight Pharma Reports is a division within Cambridge Healthtech Institute. http://www.InsightPharmaReports.com
Insight Pharma Reports offers our Affiliated Reports Collection which provides a repository of additional scientific and business resources. For more information, visit http://www.insightpharmareports.com/
# # #
Insight Pharma Reports are written by experts in consulting and industry who collaborate with us to provide a series of reports that evaluate the salient issues in pharmaceutical technology, business, and therapy markets.